Its expression is linked to a better prognosis in CRC patients, as the percentage of ICOS+ CD4+ cells operating as Th1 cells in either primary tumor tissue or peripheral blood could be a clinical predictive marker for a favorable prognosis (37). This evidence concerns the gene CD4 and neoplasm.